Clinical Trials for Non-Small Cell Lung Cancer

Phase I Study of Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors in Participants With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial involves patients with metastatic pancreatic, colorectal, or non-small cell lung cancers with the KRAS G12V mutation who are HLA-A*11:01 positive and have progressed on prior therapies; it examines the safety and efficacy of autologous CD8+ and CD4+ T cells engineered to express KRAS G12V-specific T cell receptors following lymphodepleting chemotherapy.

ClinicalTrials.gov ID: NCT06043713

A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial investigates cabozantinib, an oral tyrosine kinase inhibitor, in adult patients with advanced non-small cell lung cancer exhibiting RET, ROS1, or NTRK fusions, or increased MET or AXL activity, to assess its efficacy in tumor reduction.

ClinicalTrials.gov ID: NCT01639508

A Phase II Study of the Effects of Pembrolizumab on Quality of Life for Patients With Treatment-Naïve, Advanced or Metastatic NSCLC and Poor Performance Status

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial evaluates the effects of pembrolizumab on quality of life in treatment-naïve patients with advanced or metastatic NSCLC and poor performance status (ECOG 2 or 3) with a PD-L1 TPS ≥ 1%, who are unsuitable for standard treatments. Pembrolizumab, a PD-1 inhibitor, reactivates T-cells, aiming to improve outcomes and manage toxicity in this specific patient population.

ClinicalTrials.gov ID: NCT05589818

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients with Select Solid Tumors.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: This clinical trial evaluates the safety and efficacy of the investigational drug NEO212, a novel conjugate of temozolomide and perillyl alcohol with enhanced brain penetration, in adults with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, or uncontrolled brain metastases from select solid tumors, including combinations with standard treatments like pembrolizumab or ipilimumab.

ClinicalTrials.gov ID: NCT06047379

Phase I Trial of Feasibility and Safety of Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial investigates the safety and feasibility of combining liver SBRT with the immune checkpoint inhibitor Pembrolizumab, which targets PD-1, in adult patients with metastatic non-small cell lung cancer and liver metastases who are eligible for this immunotherapy.

ClinicalTrials.gov ID: NCT05430009

A Pilot Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This clinical trial targets patients with locally advanced or metastatic non-small cell lung cancer with an ECOG Performance Status of 2, examining the safety and efficacy of combining pembrolizumab, an anti-PD-1 monoclonal antibody, with either Pemetrexed or Nab-paclitaxel chemotherapy.

ClinicalTrials.gov ID: NCT04297605

CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with stage IV or recurrent NSCLC who have progressed after prior systemic therapy (including PD-1/PD-L1 inhibitors) and lack EGFR, ALK, or ROS1 mutations, to receive atezolizumab (PD-L1 inhibitor) plus pirfenidone, an antifibrotic agent with immunomodulatory properties. Suitable patients should have adequate organ function, ECOG 0-2, and no significant comorbidities or prior severe pneumonitis.

ClinicalTrials.gov ID: NCT04467723

A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination With Durvalumab (MEDI4736) and Chemotherapy in Untreated Patients With Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with untreated, advanced or metastatic adenocarcinoma NSCLC (EGFR/ALK/ROS1 wild-type, ECOG 0-1) to receive first-line durvalumab (anti-PD-L1 antibody) and platinum/pemetrexed chemotherapy with either restorative microbiota therapy (an oral capsule designed to modulate the gut microbiome and potentially enhance immunotherapy efficacy) or placebo. Prior systemic therapy in the advanced/metastatic setting is not permitted.

ClinicalTrials.gov ID: NCT04105270

Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with stage III NSCLC who have oligoprogressive (≤3 lesions) or polyprogressive (>3 lesions) disease after prior chemoradiation and anti-PD-L1 therapy, treating them with local consolidative therapy (radiation and/or surgery) plus durvalumab (an anti-PD-L1 antibody), with polyprogressive patients also receiving platinum-based chemotherapy. Patients with EGFR or ALK alterations and standard targeted options are excluded.

ClinicalTrials.gov ID: NCT04892953

TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with stage IV non-squamous NSCLC who have either a sensitizing EGFR exon 19 or 21 mutation (after progressing on TKI therapy) or never smokers with wild-type tumors and randomizes them to standard carboplatin, pemetrexed, and bevacizumab with or without atezolizumab, a PD-L1 immune checkpoint inhibitor. Maintenance therapy consists of pemetrexed and bevacizumab, with or without atezolizumab per treatment arm.

ClinicalTrials.gov ID: NCT03786692